Arsenal Biosciences

Edit info

Founded: 2018

Location: South SF, CA

Employee range: 1 - 10

Clinical stage: Clin0

Therapy area: Ovarian cancer

Drug types: ONC

Lead product: AB-1015

Funding: $220M B Sep 2022; $85M A Oct 2019

Investors: Westlake Village BioPartners, the Parker Institute for Cancer Immunotherapy, Kleiner Perkins, UCSF Foundation Investment Company, Euclidean Capital, Osage University Partners, Softbank Vision Fund 2, Bristol-Myers Squibb Company, Byers Capital, Emerson Collective Investments, Green Sands, Hitachi Ventures, Sixth Street

arsenalbio.com

linkedin.com

job board

Business:

Cancer Treatments

Drug notes:

AB-2100 Clin0 solid tumors

About:

ArsenalBio is developing programmable immune cell therapies to defeat cancer. CAR T-cell therapies are a recent revelation in developing targeted immune therapies for cancer. However, they have high risk and are high cost for development. Using multi-omics, gene editing technology and synthetic biology, ArsenalBio’s cell therapeutics are optimized for expansion, memory and persistence in vivo to reduce the number of cell infusions and minimize off-target effects. ArsenalBio is therefore enhancing the safety, efficacy and availability of these cell therapies for cancer patients. ArsenalBio has a multi program discovery collaboration with Bristol Myers Squibb to advance T cell therapies for solid tumors.

Scientist I, Immunohistochemistry (24218-U-670-IHC...

South San Francisco|3 days ago